Tender Details | ||||||||
|
||||||||
Deadline * | ||||||||
|
||||||||
Client Address | ||||||||
|
||||||||
More Information | ||||||||
Know More |
Similar Tenders
- Ref No: 9850247
- Location: United States
Snow Ice Removal Services Nova District Mb
- Deadline: 28 Feb 2025
- Ref No: 4641405
- Location: Germany
Medicines With The Active Ingredient Aclidinium Bromide Atc R03Bb05
- Deadline: 28 Feb 2026
- Ref No: 5393652
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Fampridine N3
- Deadline: 10 Nov 2025
- Ref No: 5837360
- Location: Germany
Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Blood Sugar Test Strips
- Deadline: 10 May 2026
- Ref No: 5227070
- Location: Germany
Medicines With The Active Ingredient Dupilumab Atc D11Ah05
- Deadline: 31 Mar 2026
- Ref No: 5229599
- Location: Germany
Medicines With The Active Ingredient Fampridine Atc N07Xx07
- Deadline: 31 Mar 2026
- Ref No: 5965414
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acarbose Not In Standard Size
- Deadline: 10 May 2026
- Ref No: 8267412
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Brinzolamide Brimonidine Atr
- Deadline: 10 May 2026
- Ref No: 8294730
- Location: Germany
Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Omalizumab
- Deadline: 10 Aug 2026
- Ref No: 8309306
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Pomalidomide
- Deadline: 10 May 2026
- Ref No: 8312368
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bosutinib
- Deadline: 10 May 2026
- Ref No: 5716614
- Location: Germany
Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Rituximab
- Deadline: 11 May 2026
- Ref No: 5718497
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab
- Deadline: 11 May 2026
- Ref No: 5728730
- Location: Germany
Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bevacizumab
- Deadline: 10 May 2026